Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

Shire

Shire to acquire Dyax in $5.9 billion deal

November 2, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease

Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …
News
neil_brewis_photo

Biopharma firm F-star appoints Dr Neil Brewis as CSO

November 2, 2015 Manufacturing and Production, Research and Development F-star, Neil Brewis

F-star, a biopharma company focused on immuno-oncology, has hired Dr Neil Brewis as chief scientific officer. Dr Brewis is a former vice …
Appointment
EU flag

European Commission funds €23m project to develop HIV vaccine

November 2, 2015 Research and Development, Sales and Marketing BioNTech, European Commission, HIV, R&D, horizon 2020

The European Commission has kicked-off a new €23 million research program to bring together researchers to work on a potential …
News
eylea

Bayer, Regeneron’s Eylea gets additional EU indication

November 2, 2015 Research and Development, Sales and Marketing Bayer, Eylea, Regeneron

The European Commission has granted a fifth indication to Bayer and Regeneron’s eye drug Eylea (aflibercept injection), which is now …
News
Merck R&D

Merck and Selvita form oncology partnership

November 2, 2015 Research and Development, Sales and Marketing Merck, Selvita, collaboration, oncology

Merck has entered a three-year agreement with Selvita to validate new therapeutic concepts in the field of oncology. The aim …
News
pillsphotos1

The pharmaceutical ethics of drug-price increases

October 30, 2015 Medical Communications, Research and Development Drug pricing, Turing Pharma, ethics

What is an ‘ethical’ price for a drug?Last month Turing Pharmaceuticals, a start-up run by a former hedge-fund manager, raised …
Feature
Coins

ANALYSIS: The challenges of forecasting biosimilar sales across Europe

October 29, 2015 Manufacturing and Production, Research and Development, Sales and Marketing biologics, biosimilars, generics, patent cliff, patents, sales, sales forecasts

The introduction of biologic medicines revolutionised treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases.The landscape …
Feature

Bayer posts strong earnings growth

October 29, 2015 Manufacturing and Production, Research and Development, Sales and Marketing

Sales across the Bayer group rose by 1.9% in the third quarter of 2015 to €11 billion, according the company’s …
News
novartis

Novartis launches new hypertension program in Ghana

October 29, 2015 Research and Development

The Novartis Foundation and its partners have begun screening patients in a Community-based Hypertension Improvement Project (ComHIP) in Ghana in …
News
jose_joe_almeida

Baxter names José Almeida chairman and chief executive

October 29, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Joe Almeida, José Almeida, baxter

Baxter has named José (Joe) Almeida as the company’s new chairman and chief executive from January 1, 2016. Almeida will …
Appointment
imlygic_amgen

FDA approves first-in-class Amgen melanoma drug

October 28, 2015 Research and Development, Sales and Marketing Amgen, Imlygic, melonoma

The US Food and Drug Administration (FDA) has approved Amgen’s Imlygic for the treatment of melanoma lesions in the skin …
News
Jinarc

Otsuka kidney drug earns first NICE nod

October 28, 2015 Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan

NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …
News
Merck image

Sales up at MSD while Keytruda hits survival target in late-stage trial

October 28, 2015 Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab

Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
News
Sativex

Otsuka, GW announce Sativex fails in Phase III cancer pain trials

October 28, 2015 Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure

Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
News
BGMA D-G Warwick Smith

OPINION: ‘More work remains if biosimilars are to fulfil their potential’

October 27, 2015 Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents

Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …
Feature
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026